Lataria E. L.

Burbello A.T., Korosteleva M.A., Lataria E.L., Pokladova M.V., Fedorenko A.S. 409

OBJECTIVES. To assess the structure of spending the financial resources of hospital for the purchase of medicines for the treatment of patients with COVID-19 on North-Western State Medical University. I.I. Mechnikov for the period of reprofiling during 2020-2021. Also to conduct a comparative analysis with the costs of treating patients who received treatment in non-reprofiled units. Materials and methods. With the help of ABC/VEN and ATC/DDD analyzes, the consumption of drugs used to treat patients with COVID-19, as well as for non-repurposed units, was estimated. Results. An analysis was made of the consumption of medicines in a medical organization during the period of re-profiling a part of the bed fund for the treatment of patients with COVID-19 in 2020-2021. Based on the results of the assessment of the structure of drug consumption, a significant excess in drug supply (for various pharmacological subgroups) of patients with COVID-19 was revealed in comparison with patients who received treatment in non-reprofiled units. Conclusion. Treatment of patients with COVID-19, subject to the methodological recommendations of the Ministry of Health for the diagnosis and treatment of a new coronavirus infection, is quite financially burdensome for a hospital. Given the shortage of drugs on the market in the conditions of the whole country at the beginning of the COVID-19 pandemic, some purchased drugs were almost completely used to treat patients of the Covid Center.

Burbello A.T., Korosteleva M.A., Lataria E.L., Pokladova M.V., Fedorenko A.S. 409

OBJECTIVES. To assess the structure of spending the financial resources of hospital for the purchase of medicines for the treatment of patients with COVID-19 on North-Western State Medical University. I.I. Mechnikov for the period of reprofiling during 2020-2021. Also to conduct a comparative analysis with the costs of treating patients who received treatment in non-reprofiled units. Materials and methods. With the help of ABC/VEN and ATC/DDD analyzes, the consumption of drugs used to treat patients with COVID-19, as well as for non-repurposed units, was estimated. Results. An analysis was made of the consumption of medicines in a medical organization during the period of re-profiling a part of the bed fund for the treatment of patients with COVID-19 in 2020-2021. Based on the results of the assessment of the structure of drug consumption, a significant excess in drug supply (for various pharmacological subgroups) of patients with COVID-19 was revealed in comparison with patients who received treatment in non-reprofiled units. Conclusion. Treatment of patients with COVID-19, subject to the methodological recommendations of the Ministry of Health for the diagnosis and treatment of a new coronavirus infection, is quite financially burdensome for a hospital. Given the shortage of drugs on the market in the conditions of the whole country at the beginning of the COVID-19 pandemic, some purchased drugs were almost completely used to treat patients of the Covid Center.